GAAP / Non-GAAP Reconciliations November 6, 2025 1 Operational change: Refers to constant currency percentage changes and is derived by translating amounts for the current period at prior year comparative period exchange rates and in doing so shows the percentage change from 2025 constant currency net sales, total revenues, adjusted EBITDA, and adjusted EPS to the corresponding amount in the prior year. This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, disseminati ...

Financial Highlights - Total revenues reached $1288 million, a 15% year-over-year increase[8] - Annual Recurring Revenues (ARR) totaled $1071 million, up 18% year-over-year, representing 832% of total revenue[8] - Cloud revenue amounted to $485 million, showing a 60% year-over-year growth[8] - A-EBITDA margin was 363%, a 130 bps increase year-over-year[8] - Free cash flows reached $101 million, a significant 1864% increase year-over-year[8] Key Metrics - Enterprise Cloud Bookings increased to $160 million, a 202% year-over-year increase[8] - The number of cloud deals exceeding $1 million reached 33, a 435% year-over-year increase[8] - Cloud Net Renewal Rate stood at 96%, a 200 bps increase[8] Future Outlook - The company anticipates total revenue growth of 1% to 2% and cloud revenue growth of 3% to 4% for F'26[21] - Enterprise Cloud Bookings are projected to grow by 12% to 16%[21] - A-EBITDA margin is expected to increase by 50 bps to 100 bps, with free cash flow growth projected at 17% to 20%[21]

NASDAQ CCOI INVESTOR PRESENTATION Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which relate to future, not past, events and are subject to risks and uncertainties. The forward-looking statements, which address the Company's expected business and financial performance, among other matters, contain words such as: "will", "expect", "believe", "continue ", "optimistic", "shou ...

Financial Performance & Growth - Total revenue reached $35.1 million, a 1% year-over-year increase, driven by strong pricing in the foundational Powdered Activated Carbon (PAC) business[7, 12] - Adjusted EBITDA was $5.2 million, marking the 6th consecutive quarter of positive Adjusted EBITDA, though negatively impacted by low volume and early Granular Activated Carbon (GAC) ramp-up[7, 12] - PAC pricing grew by 7% year-over-year, with an approximate 15% average quarterly growth in PAC Average Sales Price (ASP) since Q2 2023, showing strong visibility in PAC contract renewals into 2026 and beyond[8] - A $25+ million Adjusted EBITDA improvement has been achieved since Q3 2023 on a trailing twelve-month basis, driven by the PAC turnaround and cost management[7] GAC Business & Strategy - Initial commercial phase GAC production and sales were achieved, with robust GAC market dynamics[7] - The company is exploring blending or replacing Corbin GAC feedstock and advancing alternative product developments for Corbin feedstock[9] - The Final Investment Decision (FID) for Phase II is now anticipated to coincide with reaching Phase I GAC nameplate capacity around mid-2026[36] Market & Regulatory Landscape - Regulations could boost municipal water market demand 3-5x from approximately 170 million lb/year, serving as a major catalyst for demand and potential supply shortages[88] - The company expects the annual GAC market to grow approximately 75% to over 700 million lbs, resulting in an approximate 370 million lbs supply shortfall by 2030[103] - Approximately 35% of the approximately 153,000 public water systems in the U S are estimated to require PFAS treatment facilities by 2030[101]

Neurology Pipeline and Programs - Sangamo is focused on developing genomic medicines for debilitating neurological diseases, leveraging its zinc finger epigenetic regulation technology and AAV capsid discovery platform[3, 4] - ST-503 for small fiber neuropathy (SFN) is in Phase 1/2 clinical trials, with preliminary efficacy data expected in Q1 2027, targeting a market impacting 650,000 people across the US, Europe and Japan[12, 18, 19, 64, 65] - ST-506 for prion disease is advancing towards a CTA submission expected as early as mid-2026, with preliminary efficacy data anticipated from mid-2027, addressing a condition resulting in 1,500 deaths per year across the US, Europe and Japan[12, 21, 22, 33, 87] - The STAC-BBB capsid has demonstrated industry-leading CNS tropism in NHPs, with 700-fold higher transgene expression than benchmark capsid AAV9, and is the subject of license agreements with Genentech, Astellas and Lilly[25, 27, 92] Financial Highlights and Partnerships - Sangamo has received $88 million in cash from STAC-BBB partners to date, with up to $46 billion in potential future milestones and exercise fees assuming exercise of all options and targets, plus additional potential product royalties[26] - As of September 30, 2025, Sangamo had approximately $296 million in cash and cash equivalents, which is expected to fund planned operations into Q1 2026[34, 36] - Sangamo anticipates non-GAAP operating expenses for 2025 to be in the range of $125 million to $145 million[36] - Pfizer exercised a buyout option for a license to use certain zinc finger modified cell lines, resulting in $6 million payment to Sangamo[34] Fabry Disease Program - Positive clinical data from the registrational STAAR study in Fabry disease showed a positive mean annualized eGFR slope of 1965 mL/min/173m2/year (95% CI: -0153, 4083) at 52-weeks across all 32 dosed patients[33] - Sangamo is preparing for an anticipated BLA submission for Isaralgagene civaparvovec as early as the first quarter of 2026, while continuing business development discussions for a Fabry commercialization agreement[28, 33, 124]

Acquisition Overview - Schwab is acquiring Forge Global to enhance its presence in private markets[1, 41] - The acquisition aims to create a best-in-class experience for individual investors and RIAs in both public and private markets[10, 36] - The deal involves Schwab acquiring all outstanding common stock of Forge for $45 per share, equating to an implied equity value of $660 million[34] - The transaction is expected to close in the first half of 2026, subject to regulatory approvals and customary closing conditions[34] Forge Global's Key Metrics - Forge operates a technology-enabled marketplace for trading shares in pre-IPO companies, founded in 2014[12] - Forge's platform has facilitated over $17 billion in private market transaction volume[11, 13] - The platform supports trading in over 625 private companies and has over 3 million unique users[11, 13] - Forge's private asset AUC (Assets Under Custody) is over $18 billion[13] - Forge's total revenue grew by 24% from Q2 2024 to Q2 2025[13] Market Trends and Opportunities - Industry trends indicate a growing interest in private markets due to companies staying private longer and a decline of approximately 85% in the number of IPOs per year since 2000[14, 15] - Median IPO valuations are up more than 3x versus 2000[15] - Private wealth capital allocated to alternatives is expected to reach approximately $13 trillion by 2032, representing a 13% CAGR (Compound Annual Growth Rate)[16, 19] Strategic Benefits for Schwab - The acquisition diversifies Schwab's revenue mix and supports long-term organic growth[38, 40] - It enhances Schwab's competitive positioning and evolves its offerings to retail and RIA clients[38, 40] - The acquisition strengthens Schwab's Workplace Services solution set[38, 40]

Financial Performance - Total revenue for Q3 2025 reached $87.3 million, a 69% year-over-year increase[7, 31] - U S net product sales for Q3 2025 were $40.7 million, representing a 31% year-over-year growth[7, 31] - Collaboration revenue increased by 128% year-over-year, reaching $46.7 million in Q3 2025[31] - Esperion closed a $75 million follow-on equity offering, resulting in net proceeds of approximately $72.6 million[31] Market Access and Expansion - Retail prescription equivalents increased by 9% quarter-over-quarter[8, 39] - The total prescriber base now exceeds 30,000 healthcare professionals[10] - Medicare coverage reached 87% and commercial coverage reached 86%[13] Guideline Recognition and Strategic Partnerships - Bempedoic acid received a Level 1a recommendation in the updated ESC/EAS Guidelines for Management of Dyslipidemia[8, 15] - Esperion has partnerships in over 40 countries globally, including Europe, Japan, Asia, South America, Israel, Australia & New Zealand, and Canada[19] Pipeline and Future Outlook - Triple Combination A and B are projected to have NDA filings in 2027[25] - The company expects market approval in Canada in Q4 2025[19]

Q3 2025 Performance - RXO's Q3 2025 revenue was $1421 million [12] - Adjusted EBITDA for Q3 2025 was $32 million [12] - Q3 2025 adjusted diluted EPS was $001 [25] - Q3 adjusted free cash flow conversion was 56% [28] - Gross margin was $234 million [12] Operational Highlights - Truckload (TL) volume was down 11% year-over-year (y/y), representing 69% of total volume, while Less-Than-Truckload (LTL) volume was up 43% y/y, accounting for 31% of volume [15] - Last Mile stop growth increased by 12% y/y [15] - Productivity gains in brokerage increased by 19% [15] Cost Savings Initiatives - Total annualized operating expense reductions are expected to be greater than $155 million, including over $60 million from Coyote synergies [18] - The company anticipates approximately 100 basis points of savings/avoidance in Cost of Purchased Transportation (COPT) [17] Q4 2025 Outlook - Adjusted EBITDA is projected to be between $20 million and $30 million [51] - Brokerage volume is expected to decrease by a low-single-digit percentage y/y [51] - Brokerage gross margin is anticipated to be in the range of 12%-13% [51] Capital Structure - Net debt stood at $395 million [32] - Gross leverage was 24x, and net leverage was 23x [33]

Strategic Transformation - Galapagos is executing a strategic transformation, including the intention to wind down the cell therapy business, subject to works council consultations[13, 17] - The company expects to be cash flow neutral to positive by YE26, excluding BD and currency fluctuations[18] - A lean organization of 35-40 employees is expected by YE26, focused on transformative business development[18, 60] Financial Performance & Outlook - Nine-month total revenues increased by 6% to €211.4 million[64] - R&D expenses increased by 48% to €351.9 million[64] - An impairment loss of €204.8 million was recorded for the Cell Therapy business[64, 70] - The company anticipates approximately €2.975 - €3.025 billion in cash and investments at YE25[24] Business Development Strategy - Business development is a core strategy, leveraging a unique partnership with Gilead[37, 38] - The company is open to opportunities across diseases, modalities, geographies, and deal types[51] - A disciplined approach to capital deployment aims to maximize near- and long-term value creation[39, 40]

Q3 2025 Financial Performance - Net sales were $1.3 billion, a decrease of 4% year-over-year[13, 18] - Adjusted EBITDA increased by 7% year-over-year to $226 million, driven by cost and efficiency improvements offsetting lower lithium pricing[13, 18] - Q3 cash from operations increased by 57% year-over-year to $356 million, with year-to-date cash from operations up 29% year-over-year to $894 million[13] - The adjusted EBITDA margin was 17%, an increase of 150 basis points compared to the previous year[18] - Adjusted diluted loss per share attributable to common shareholders improved by 88% to ($0.19)[18] Outlook and Strategy - The company expects to achieve positive free cash flow of $300-400 million in 2025[13] - FY 2025 results are expected to be towards the higher end of the previously published $9/kg scenario ranges[13, 22] - FY 2025 capital expenditures outlook reduced to approximately $600 million[13] - Agreements to sell stakes in Ketjen and Eurecat JV for expected combined pre-tax cash proceeds of approximately $660 million[13, 17] Market Trends - Global EV sales increased by 30% year-over-year through September, led by China and Europe BEVs[13, 37] - ESS battery demand increased by 105% year-over-year through September, driven by strong growth in the US, Europe, and China[13, 42]